Serina Therapeutics (SER) EBITDA (2018 - 2026)
Serina Therapeutics (SER) posted EBITDA of -$6.2 million for Q4 2025, up 2.89% sequentially from -$6.4 million in Q3 2025, and down 11.86% YoY from -$7.0 million in Q4 2024.
Serina Therapeutics (SER) EBITDA (2018 - 2026) Analysis & Trends
Serina Therapeutics has reported EBITDA for 8 years, with the latest figure at -$6.2 million in Q4 2025.
- Quarterly EBITDA fell 11.86% year-over-year to -$6.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$24.0 million (down 40.91% YoY) and the FY2025 annual result came in at -$24.0 million, down 40.91% from the prior year.
- EBITDA rose to -$6.2 million in Q4 2025 per SER's latest filing, from -$6.4 million in the prior quarter.
- Over five years, EBITDA peaked at $241000.0 in Q4 2023 and troughed at -$6.4 million in Q3 2025.
- A 5-year average of -$3.0 million and a median of -$2.1 million in 2021 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2024: EBITDA surged 113.52% in 2023, then tumbled 2402.49% in 2024.
- Over 5 years, EBITDA stood at -$1.9 million in 2021, then advanced by 4.55% to -$1.8 million in 2022, then soared by 113.52% to $241000.0 in 2023, then sank by 2402.49% to -$5.5 million in 2024, then retreated by 11.86% to -$6.2 million in 2025.
- According to Business Quant data, EBITDA over the past three periods registered -$6.2 million, -$6.4 million, and -$5.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 133.12 Mn |
| 10 | Serina Therapeutics | 43.09 Mn | 20.07 Mn | - | -6.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.78 Mn |
| Dec 31, 2025 | -6.21 Mn |
| Sep 30, 2025 | -6.39 Mn |
| Jun 30, 2025 | -5.57 Mn |
| Mar 31, 2025 | -5.86 Mn |
| Dec 31, 2024 | -5.55 Mn |
| Sep 30, 2024 | -5.31 Mn |
| Jun 30, 2024 | -3.87 Mn |
| Mar 31, 2024 | -2.32 Mn |
| Dec 31, 2023 | 241,000.00 |
| Sep 30, 2023 | -1.46 Mn |
| Jun 30, 2023 | -945,000.00 |
| Mar 31, 2023 | -962,000.00 |
| Dec 31, 2022 | -1.78 Mn |
| Sep 30, 2022 | -1.55 Mn |
| Jun 30, 2022 | -1.59 Mn |
| Mar 31, 2022 | -2.05 Mn |
| Dec 31, 2021 | -1.87 Mn |
| Sep 30, 2021 | -1.67 Mn |
| Jun 30, 2021 | -2.21 Mn |